This paper is in the following e-collection/theme issue:

Participatory Research Protocols and Proposals (165) Precision Medicine (116) Infectious Diseases (non-STD/STI) (1668) Influenza and Influenza-Like-Illness (ILI) Surveillance (227) Clinical Information and Decision Making (1716)

Published on in Vol 13 (2024)

This is a member publication of Bodleian Libraries (Jisc)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56271, first published .
Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study

Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study

Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study

Authors of this article:

Meredith Leston1 Author Orcid Image ;   José Ordóñez-Mena1 Author Orcid Image ;   Mark Joy1 Author Orcid Image ;   Simon de Lusignan1 Author Orcid Image ;   Richard Hobbs1 Author Orcid Image ;   Iain McInnes2 Author Orcid Image ;   Lennard Lee3 Author Orcid Image
Article Authors Cited by (2) Tweetations (4) Metrics

Journals

  1. Leston M, Kar D, Forbes A, Jamie G, Wimalaratna R, Jiwani G, Ordóñez-Mena J, Stewart D, Whitaker H, Joy M, Lee L, Hobbs F, de Lusignan S. Developing a digital phenotype to subdivide adult immunosuppressed COVID-19 outcomes within the English Primary Care Sentinel Network. Frontiers in Immunology 2024;15 View
  2. Leston M, Ordóñez-Mena J, Joy M, Hobbs F, de Lusignan S, Teh B, de Groot I, McInnes I, El Sahly H, Isaacs J, Andersson M, Raffi F, Lim W, Conway R, Siebert S, Buchan I, Underwood M, Lowe D, Hoerger M, Griffiths C, Alunno A, Lee L. The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles. eClinicalMedicine 2025;83:103239 View